Strides Pharma Science ↗

In FY26, the company reported TOI at ₹4,933 crore compared to ₹4,572 crore in FY25, reflecting a modest growth of ~8%, largely aided by favourable currency movements. Growth in FY26 remained modest due to the discontinuation of nine low-margin products in the US, a weaker flu season in its key market, the US, and reduced sales from low-margin donor-funded business. Geographically, America continued to be the largest contributor, accounting for ~54% of revenue, registering marginal growth of

The company’s overall financial risk profile witnessed an improvement marked by its overall gearing and TOL/TNW of 0.73x (FY25: 0.97x) and 1.43x (FY25: 1.64x), respectively, as of FY26-end. The company’s total debt reduced by ~₹1,150 crore despite adverse currency fluctuations in last four years ended FY26 backed by scheduled repayments, transfer of partial debt as part of the business restructuring exercise and lower working capital borrowings backed by healthy cashflow from operations.

Strides has an established track record of over three decades in the pharmaceutical sector and has undergone acquisitions / divestments in its operations. The promoter, Arun Kumar, brings over three decades of experience in the pharmaceutical indust ry. He has a proven track record of acquiring distressed assets, successfully turning around their operations, and creating value through profitable monetisation. Strides' growth strategy is driven by a balanced mix of organic expansion and strategic

Strides has gradually diversified its geographical presence beyond the US market by strengthening its presence across other regulated markets, including Europe, the UK, Australia, Canada and the Nordics, while simultaneously expanding its footprint in 2 CARE Ratings Ltd. Press Release emerging markets, such as Africa, Latin America (LATAM), the Middle East and North Africa (MENA), and Asia-Pacific (APAC). Consequently, company’s revenue from Ex-US markets (excluding access markets, which largely

Strides maintains a well-diversified product portfolio with low product concentration risk, with no single product accounting for a significant share of overall revenue. Contribution from top 10 products remained at ~30% in FY26 (FY25: 35%), reflecting successful commercialisation of new products and a progressively balanced revenue mix. The company has a robust pipeline comprising 220+ abbreviated new drug application (ANDA) filings, of which 208 have been approved across different therapeutic

Strides' operations remain inherently working capital intensive, given the need to maintain inventory across multiple geographies and regulated markets to ensure uninterrupted product availability, and credit period extended to customers. In FY26, the company's GCA days increased to 252 days (FY25: 232 days), primarily due to a conscious build-up of inventory to mitigate potential supply chain disruptions arising from the West Asia crisis. Incremental working capital requirement was largely supp

Strides remains exposed to regulatory risks inherent in the pharmaceutical industry, with a significant portion of its revenue derived from regulated markets, particularly the US, Europe, Australia, and the UK. Manufacturing facilities and products are subject to stringent regulatory requirements, including periodic inspections by global regulatory authorities,such as the USFDA. Adverse regulatory action, including delays in product approvals, import alerts, warning letters, or restrictions on m

Strides remains exposed to fluctuations in foreign exchange rates and raw material prices, given its significant presence in international markets and dependence on imported inputs. The company derives its entire revenue from overseas markets, making its earnings susceptible to currency movements. In FY26, Strides benefitted from favourable foreign exchange movements, which supported revenue growth and operating profitability. However, its foreign currency-denominated borrowings also resulted in